Check the appropriate box:

     ☐          

Preliminary Proxy Statement

☐    

CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))

☐    

Definitive Proxy Statement

☑    

Definitive Additional Materials

☐    

Soliciting Material Pursuant to Section 240.14a-12

Payment of filing fee (check the appropriate box):

     ☑          

No fee required.

☐    

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

(1) 

Title of each class of securities to which transaction applies:

(2) 

Aggregate number of securities to which transaction applies:

(3) 

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) 

Proposed maximum aggregate value of transaction:

(5) 

Total fee paid:

☐    

Fee paid previously with preliminary materials.

☐    

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the  offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule  and the date of its filing.

(1) 

Amount Previously Paid:

(2) 

Form, Schedule or Registration Statement No.:

(3) 

Filing Party:

(4) 

Date Filed:

After achieving our 2013-2020 conservation targets, in January, we launched our new environmental sustainability plan that includes a goal of achieving carbon neutrality in our owned and operated facilities by 2027 (while also reducing water use by 40% and waste disposed by 75%⁽²⁾).

Since its inception, The Amgen Foundation, Inc., a separate legal entity entirely funded by Amgen, has contributed more than $350 million to non-profit organizations across the world that reflect our core values and complement Amgen’s purpose-driven dedication to impacting lives in inspiring and innovative ways.

Through patient assistance programs, expanded access to investigational therapies, donations, and other efforts, we have developed patient support programs worldwide to assist eligible patients to obtain the medicines they need.

We increased our focus on diversity, inclusion, and belonging, including by becoming a founding member of OneTen, a coalition of more than 40 of the world’s largest, best-known companies, that aims collectively to hire one million Black Americans (with a specific focus on those without four-year college degrees) into good-paying, family-sustaining jobs over the next ten years, and as a founding sponsor of Lazarex Cancer Foundation’s IMPACT (Improving Patient Access to Cancer Clinical Trials) program, focused on improving patient enrollment, minority participation, and equitable access in cancer clinical trials.

FOR each

Director Nominee

Our Board consists of a diverse group of highly qualified leaders in their respective fields. Many of our directors have:

Senior leadership experience at large companies and have gained significant and wide-ranging management experience.

Public company experience, an understanding of corporate governance practices and trends, and bring a unique perspective to the Board.

Extensive scientific and healthcare expertise relevant to our industry, including pioneering scientific research in the areas of oncology and cardiology.

Our lead independent director, Robert A. Eckert, has substantial and specific duties and has been elected by our Board to serve as the lead independent director in 2021 subject to his re-election to the Board by stockholders.

We have a highly independent Board (10 of our 11 director nominees are independent) and only independent Board members serve on key standing committees⁽³⁾.

Key standing committees of the Board include the Audit, Compensation and Management Development, Corporate Responsibility and Compliance, and Governance and Nominating Committees.

We have a long-standing practice of stockholder engagement throughout the year and at our Annual Meeting. Since our 2020 annual meeting of stockholders, we have engaged in governance-focused outreach activities and discussions with stockholders owning ~54% of our outstanding shares.

Discovering and advancing innovative medicines that address important unmet medical needs.

We successfully integrated our acquisition of Otezla^®.

We executed key clinical studies and advanced an innovative first-in-class pipeline delivering positive registration-enabling results, including for sotorasib (our KRAS^G12C small molecule inhibitor being investigated as a treatment for a variety of solid tumors) and tezepelumab⁽⁴⁾ (an investigational therapy that blocks the action of thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a key role across the spectrum of asthma inflammation). The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for both sotorasib and tezepelumab. Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition.

We continued to advance our early pipeline. We formed eight new product teams (formed when a molecule has been judged to have the potential to be safe and effective in humans), initiated six first-in-human studies, and advanced two programs through our early-to-late stage portal.

Developing branded biosimilars.

We launched AVSOLA® (biosimilar infliximab (Remicade®⁽⁵⁾)) and, in 2020, we received approval of RIABNI^™ (biosimilar rituximab (Rituxan®⁽⁶⁾)) and launched it in 2021.

Transforming Amgen for the future.

We continued to realize gross productivity savings ($304 million in 2020) which we reinvested in our business.

Adhering to a disciplined approach to capital allocation while investing for long-term growth.

We invested $4.2 billion in research and development, $0.6 billion in capital projects, and $3.35 billion in BeiGene, Ltd.

We also returned in excess of $7 billion of capital to stockholders in the form of dividends paid ($3.8 billion) and repurchases of our Common Stock ($3.5 billion).

Expanding our global geographic reach.

We began our strategic collaboration with BeiGene, Ltd. to expand our oncology presence in China.

XGEVA® and BLINCYTO® were approved in China and KYPROLIS® is under review.

XGEVA was added to the National Reimbursement Drug List in China.

We established our wholly-owned affiliate in Japan with the acquisition of Amgen Astellas BioPharma K.K.

Successfully operating our next-generation biomanufacturing facility in Singapore since 2017 and delivering cost and environmental efficiencies. Success of our facility in Singapore, along with U.S. corporation tax reform, led to our building a second such plant in Rhode Island, our first U.S.

next-generation biomanufacturing plant that, upon approval by global regulatory authorities, will expand our manufacturing capacity, while also delivering these efficiencies.

Our next-generation biomanufacturing approach dramatically reduces the scale and costs of making biologics, vastly reducing water and energy use, while maintaining a reliable, high-quality, compliant supply of medicines.

For 2020, particularly during the initial stages of the COVID-19 pandemic, we experienced changes in demand for some of our products as physician-patient interactions were interrupted, which led to delays in diagnosis and treatment with varying degrees of impact across our portfolio. However, despite the effects of the pandemic, we outperformed our budgeted financial targets (established in advance of the onset of the pandemic) as we drove product volume growth (including increases in EVENITY®, Repatha®, Aimovig®, and Prolia® sales) and, following our successful integration, delivered strong Otezla sales in its first full year in our product portfolio.

Our non-GAAP⁽⁷⁾ net income performance also benefited from our strong sales performance, as well as our cost efficient mitigation of the challenges and risks of the pandemic, and continued savings from efficiencies resulting from our strong performance on our productivity objective that was used to reinvest in our business.

We delivered long-term stockholder value and returns, including three- and five-year total shareholder returns of 44% and 63%, respectively, outperforming our peer group.

We established the goals for our annual cash incentive award and long-term incentive equity award programs prior to the World Health Organization (WHO) declaration of the COVID-19 global pandemic. Since then, we have not made any changes to these goals. Thus, performance reported is against goals established prior to the pandemic.

We pay for performance, and pay outcomes reflect the achievements of our Named Executive Officers, or NEOs, against our short- and long-term performance.

76% of my 2020 target direct compensation and 70% of our other NEOs’ target direct compensation was based solely on our Company’s performance.

91% of my 2020 target direct compensation and 83% of our other NEOs’ target direct compensation is “at-risk.”

Our Compensation and Management Development Committee approves Company goals each year that are designed to focus our NEOs and all of our staff members on delivering our financial and operational objectives to drive annual performance, advance strategic priorities (discussed above), and position us for longer-term success.

A substantial majority of our NEO compensation is performance-based (including 80% of total target equity, of which 50% are three-year performance awards and 30% are stock options).

In addition to our existing annual cash incentive award recoupment policy, we recently updated recoupment provisions for misconduct to include forfeiture and cancellation of unvested or unexercised equity awards, and we have a clawback policy tied to financial restatements.

We have robust stock ownership and retention guidelines.

Non-Generally Accepted Accounting Principles.